Impact of Dose Selection Strategies Used in Phase II on the Probability of Success in Phase III

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Statistics in Biopharmaceutical Research

• Publication date

  2010-11-01

• Fields of study

  Medicine, Mathematics

• Identifiers
  DOI 10.1198/sbr.2010.08101
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Discussion of “Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations”

  2010cited by this paper
• A Simulation Study to Compare New Adaptive Dose–Ranging Designs

  2010cited by this paper
• Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations. White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Studies

  2010cited by this paper
• The Bias Issue Under the Complete Null With Response Adaptive Randomization: Commentary on “Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendation”

  2010cited by this paper
• A Perspective on Characterizing Benefits and Risks Derived from Clinical Trials: Can We Do More?

  2008cited by this paper
• Adaptive dose finding based on t‐statistic for dose–response trials

  2008cited by this paper
• Discussion of “The White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Designs”

  2007cited by this paper
• Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials

  2007cited by this paper
• Adaptive designs for dose-finding based on efficacy–toxicity response

  2006cited by this paper
• Combining Multiple Comparisons and Modeling Techniques in Dose‐Response Studies

  2005cited by this paper
• ASTIN: a Bayesian adaptive dose–response trial in acute stroke

  2005influential reference
• Adaptive Bayesian Designs for Dose-Ranging Drug Trials

  2002cited by this paper
• Prospective validation of clinically important changes in pain severity measured on a visual analog scale.

  2001cited by this paper
• A Multiple Comparison Procedure for Comparing Several Treatments with a Control

  1955influential reference

• Phase 2 Design Considerations from a Program Perspective

  2026cites this paper
• Decision‐Making Criteria and Methods for Initiating Late‐Stage Clinical Trials in Drug Development From a Multi‐Stakeholder Perspective: A Scoping Review

  2025influential citation
• A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies

  2024cites this paper
• Design and sample size determination for multiple‐dose randomized phase II trials for dose optimization

  2023cites this paper
• Chemical composition and in vivo/in silico anti-inflammatory activity of an antioxidant, non-toxic essential oil from Thymus algeriensis Boiss & Reut

  2023cites this paper
• Confirmatory efficacy testing for individual dose–placebo comparisons using serial gatekeeping procedure in dose‐finding trials with multiple comparison procedures–modeling

  2022cites this paper
• Disease Modeling and Model‐Based Meta‐Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer’s Disease

  2022cites this paper
• Opportunity for efficiency in clinical development: An overview of adaptive clinical trial designs and innovative machine learning tools, with examples from the cardiovascular field.

  2021cites this paper
• Utility-Based Dose Selection for Phase II Dose-Finding Studies

  2021cites this paper
• Patient Benefits from Innovative Designs in Rare Diseases

  2021cites this paper
• Monte Carlo Simulation for Trial Design Tool

  2020cites this paper
• Point and interval estimation of the target dose using weighted regression modelling

  2020cites this paper
• Design optimization for dose-finding trials: a review

  2020cites this paper
• Monte Carlo Simulation for Trial Design Tool

  2020cites this paper
• Utility-based optimization of phase II / phase III clinical development

  2019cites this paper
• Dose Finding in the Clinical Development of 60 US Food and Drug Administration–Approved Drugs Compared With Learning vs. Confirming Recommendations

  2019cites this paper
• A modelling framework for improved design and decision-making in drug development

  2019cites this paper
• Utility-Based Dose-Finding in Practice: Some Empirical Contributions and Recommendations

  2019cites this paper
• A decision theoretical modeling for Phase III investments and drug licensing

  2018cites this paper
• Impact of Platform Trials on Pharmaceutical Frameworks

  2018cites this paper
• Optimal planning of phase II/III programs for clinical trials with multiple endpoints

  2018cites this paper
• An Adaptive Staggered Dose Design for a Normal Endpoint

  2015cites this paper
• Reflections on the adaptive designs accelerating promising trials into treatments (ADAPT-IT) process—Findings from a qualitative study

  2015cites this paper
• Improving Productivity in Pharmaceutical Research and Development : The Role of Clinical Pharmacology and Experimental Medicine

  2015cites this paper
• Need for Optimal Design of Pharmaceutical Programs and Portfolios in Modern Medical Product Development

  2015cites this paper
• Impact of Phase 2b Strategies on Optimization of Drug Development Programs

  2015cites this paper
• Dynamically Optimizing Budget Allocation for Phase 3 Drug Development Portfolios Incorporating Uncertainty in the Pipeline

  2015cites this paper
• Designing Multi-arm Multi-stage Clinical Studies

  2014cites this paper
• Pharmacometrics: Focus on the Patient

  2014cites this paper
• A Practical Guide to Data Monitoring Committees in Adaptive Trials

  2014cites this paper
• Adaptive Design Applied to Identification of the Minimum Effective Dose in Schizophrenia

  2014cites this paper
• The Need for and the Future of Adaptive Designs in Clinical Development

  2014cites this paper
• Regulatory Guidance Documents on Adaptive Designs: An Industry Perspective

  2014cites this paper
• Considerations on covariates and endpoints in multi‐arm multi‐stage clinical trials selecting all promising treatments

  2013cites this paper
• On the choice of doses for phase III clinical trials

  2013cites this paper
• Optimizing Drug Development Programs: Type 2 Diabetes Case Study

  2013cites this paper
• A contribution to the design and analysis of phase III clinical trials

  2013influential citation
• Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy.

  2013cites this paper
• A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk

  2013cites this paper
• An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project.

  2012cites this paper
• Designing Phase 2 Trials Based on Program-Level Considerations: A Case Study for Neuropathic Pain

  2012cites this paper
• Group sequential and adaptive methods - topics with applications for clinical trials

  2011influential citation
• Optimal designs for dose finding studies with an active control

  2011cites this paper
• Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication

  2011cites this paper
• From Adaptive Design to Modern Protocol Design for Drug Development: Part II. Success Probabilities and Effect Estimates for Phase 3 Development Programs

  2010cites this paper
• The Bias Issue Under the Complete Null With Response Adaptive Randomization: Commentary on “Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendation”

  2010cites this paper
• Evaluation and Recommendations on Adaptive Dose‐Ranging Trials: Highlights From the PhRMA Adaptive Dose‐Ranging Studies Working Group

  2010cites this paper
• Discussion of “Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations”

  2010cites this paper
• Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations. White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Studies

  2010influential citation
• A Simulation Study to Compare New Adaptive Dose–Ranging Designs

  2010cites this paper
• Impact of Dose Selection Strategies on the Success of Drug Development Programmes

  2009cites this paper